Arabic Arabic English English French French German German
dark

CureVac Swiss AG initiates rolling submission process for mRNA-based COVID-19 vaccine candidate, CVnCoV, with Swissmedic

CureVacThe CureVac Swiss AG, the Swiss subsidiary of CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), announced initiation of a rolling submission for CVnCoV, the company’s mRNA based COVID-19 vaccine candidate, for the use in Switzerland.

Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Lilly, Incyte report positive results for baricitinib in alopecia areata

Next Post

Adaptimmune to Report Q1 2021 Financial Results and Business Update on Thursday, May 6, 2021

Related Posts
Total
0
Share